© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2016
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Conferences

Coffee Could Protect Against Non-Alcoholic Fatty Liver Disease

Consuming coffee, even decaf, could protect against non-alcoholic fatty liver disease (NAFLD), according to a mouse study.

Success for 8 Weeks of Gilead’s All-Genotype Hepatitis C Regimen

Gilead’s experimental hepatitis C treatment for all genotypes boasted a high success rate among those treated for the first time.

People Beat Hepatitis C Just As Well When Treated by Nonspecialists

People who receive hepatitis C treatment from community-based treatment providers are cured at the same rate as those who see specialists.

Studies to Begin of $300 Generic Hepatitis C Treatment for International Use

Researchers are launching trials of a $300 generic hepatitis C regimen that could help expand treatment of the virus in poorer nations.
Thinkstock

Whether a Liver Transplant Has Hepatitis C Has No Bearing on Outcome for People With Hep C

People with hepatitis C do just as well with a liver transplant that is infected with the virus as those receiving an uninfected organ.

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics
Jeff Lazarus

Without a Vaccine, Eliminating Hepatitis C Will Be a Huge Challenge

Jeffrey Lazarus interviews experts from the European Liver Patients Association about the changing field of viral hepatitis

AbbVie’s Viekira Pak Works Just As Well in Those With Hepatitis C Drug Resistance

Having resistance to a particular class of hepatitis C drugs does not affect the likelihood of a cure with AbbVie’s Viekira Pak.

New Tenofovir Is As Good As, Safer Than Old Version for Hepatitis B

Gilead’s tenofovir alafenamide (TAF) combats hepatitis B comparably to and is safer than Viread (tenofovir disoproxil fumarate, or TDF).

Excellent Real-World Results for AbbVie’s Hepatitis C Regimen Viekira Pak

AbbVie’s hepatitis C virus (HCV) regimen Viekira Pak boasted excellent safety and efficacy data in a large, ongoing, real-world trial.

New Algorithm Predicts Who Will Benefit From End-Stage Liver Disease Treatment

Researchers have developed a new algorithm to predict who will benefit from intensive care unit treatment of end-stage liver disease.

Hot topics

Forums: Support and discussion
Blogs: The community speaks
Jeff Lazarus

Hepatitis: The International Liver Congress Nine Years Later

Jeffrey Lazarus talks here about the changes he has seen in the hepatitis field since the International Liver Congress in 2007.

Can You Get Away With an Even Shorter Hepatitis C Treatment?

Research suggests that some people are taking hep C therapy for longer periods than they actually need.

European HIV-Positive Gay Men Cured of Hepatitis C Are Reinfected at Very High Rate

Western European men who have sex with men who have HIV and are cured of hepatitis C virus are reinfected with HCV at a very high rate.

Those Who Fail Hepatitis C Treatment Have an Excellent Subsequent Shot

People retreated for hepatitis C virus after a failed cure attempt have a very good chance of achieving a cure.
Grace Campbell

Hepatitis C: A weekend of watching EASL’s Liver Conference

Pretty snappy heading, isn’t it. But it’s what I actually did. Via Twitter. So I got a lot of the info and got to skip the queues for taxis.
Advertisement
Science News
Newsfeed
Features
Ask Hep